China's export restrictions have driven antimony prices to $55,000-60,000/tonne (up 200%+ since mid-2024), creating an unprecedented investment opportunity in the extremely limited universe of publicly-traded antimony producers. Larvotto Resources and United States Antimony Corporation emerge as the top pure-play options, while Perpetua Resources offers the largest U.S. reserve with substantial government backing. Only 4-5 companies globally offer meaningful antimony exposure to investors—the rest on the initial screening list have minimal or zero antimony relevance.
The critical challenge: China controls 70%+ of global antimony processing capacity, meaning even Western miners must ship concentrate to Chinese smelters. This bottleneck defines which companies can actually benefit from elevated prices versus those that merely have antimony in the ground.
Of the 16 companies initially listed for investigation, only 6-7 offer material antimony exposure. Several were incorrectly classified or have since been acquired:
| Company | Status | Antimony Relevance |
|---|---|---|
| Larvotto Resources (LRV.AX) | Development | PRIMARY - 7% of global supply by Q2 2026 |
| United States Antimony (UAMY) | Producing | PRIMARY - ~90% revenue from antimony |
| Perpetua Resources (PPTA) | Development | BYPRODUCT - 35% of U.S. demand (2028) |
| Mandalay/Alkane (ALK.ASX) | Producing | DUAL - 1,100-1,300t Sb/year |
| Nova Minerals (NVA.AX) | Development | EMERGING - $43.4M DOD funding |
| Military Metals (MILI.V) | Exploration | PURE-PLAY - Early stage |
| Southern Cross Gold (SXG) | Exploration | BYPRODUCT - 21-24% of value |
| Americas Gold & Silver (USAS) | Producing | BYPRODUCT - 561K lbs (2025) |
| Hillgrove Resources (HGO.AX) | Producing | NONE - Copper producer |
| Investigator Resources (IVR.AX) | Development | NONE - Silver company |
| Cantex, Murchison, Salazar | Exploration | NONE - No antimony projects |
| Toachi Mining | N/A | DELISTED - Acquired 2019 |
The genuine investment universe comprises 8 companies with varying degrees of antimony leverage, from ~90% revenue exposure (UAMY) down to byproduct optionality (USAS, PPTA).
China's August 2024 export controls and December 2024 full ban on U.S. military end-users created a structural supply deficit of 34,000-39,000 tonnes in 2025. Prices peaked at $59,750/tonne in July 2025—the highest level ever recorded since Fastmarkets began tracking in the 1980s.
End market demand breakdown shows defense criticality:
The U.S. government has responded aggressively. The Defense Logistics Agency awarded $245 million to UAMY for stockpile replenishment, while the DoD committed $80+ million to Perpetua Resources and $43.4 million to Nova Minerals. The April 2025 "One Big Beautiful Bill Act" allocated $7.5 billion for critical minerals, including $2 billion to expand the National Defense Stockpile.
China's partial suspension of the export ban through November 2027 has moderated prices from their peak, but structural supply constraints remain. Global processing outside China is limited to UAMY's Thompson Falls smelter (expanding), the Sunshine Silver Refinery (targeting 2028), and scattered small-scale facilities in Belgium, Oman, Vietnam, and Thailand.
Larvotto Resources (LRV.AX) — A$655-670M market cap Larvotto owns Australia's largest and the world's 8th-largest antimony deposit at Hillgrove, NSW. The May 2025 DFS shows exceptional economics:
UAMY submitted a $470M acquisition offer in October 2025, which Larvotto's board rejected as "materially undervaluing" the company. The 7-year offtake with Wogen Resources and A$6M prepayment derisk the project significantly.
United States Antimony (UAMY) — $830M-$1.16B market cap The only fully integrated antimony producer outside China/Russia, UAMY derives ~90% of revenue from antimony—making it the purest play available. Key metrics:
The stock trades at 11.58x price/book and negative EBITDA—expensive relative to fundamentals but reflecting strategic scarcity value. HC Wainwright rates it Buy with $10.25 target.
Perpetua Resources (PPTA) — $3.2-3.4B market cap Stibnite represents the only known U.S. antimony reserve (148M lbs) and could supply 35% of domestic demand for the first six years. However, antimony is a byproduct—gold drives ~90% of expected revenue.
Strategic investments from Agnico Eagle ($255M) and $78M equity offering demonstrate institutional confidence, but this is fundamentally a gold stock with antimony optionality.
Mandalay Resources/Alkane (ALK.ASX) — A$1.0B combined market cap The August 2025 merger created Australia's largest gold producer with antimony exposure via Costerfield mine:
This is the only profitable antimony producer in the peer group, generating $69M FCF in 2024. The True Blue prospect could replicate Costerfield's success with 4km strike potential.
Americas Gold & Silver (USAS) — TSX: USA An overlooked antimony opportunity via the Galena Complex in Idaho:
Nova Minerals (NVA.AX) — A$270-514M market cap The Estelle project in Alaska has DOD backing and strategic positioning:
Identified as one of only 9 potentially viable near-term antimony projects globally by RFC Ambrian.
Southern Cross Gold (SXG.AX) — A$1.43B market cap Sunday Creek has delivered exceptional drill results (73 intercepts >100 g/t gold; 90 intercepts >10% Sb) but remains pre-resource:
Premium valuation (A$1.4B for exploration stage) reflects exceptional geology but carries execution risk.
Military Metals (MILI.V) — CAD $20-30M market cap Pure-play antimony explorer with projects in Slovakia (EU critical minerals) and Nova Scotia:
High-risk/high-reward with maximum leverage to antimony prices upon resource confirmation.
| Company | Market Cap | EV/EBITDA | P/E | Net Cash | Sb % Revenue | Production Status |
|---|---|---|---|---|---|---|
| UAMY | $830M-$1.16B | N/M (neg) | N/M | $90M+ | ~90% | Producing |
| PPTA | $3.2-3.4B | N/M (pre) | N/M | $446M | ~10% (byproduct) | Development |
| ALK/MND | A$1.0B | 2.01x | 3.2-6.4x | $88M | ~15% | Producing |
| LRV | A$655-670M | N/M (pre) | N/M | A$13M | ~35-40% | Development |
| NVA | A$270-514M | N/M (pre) | N/M | A$86M+ | Emerging | Development |
| SXG | A$1.43B | N/M (expl) | N/M | A$13M | ~21-24% | Exploration |
| MILI | CAD $21M | N/M (expl) | N/M | CAD $3M | 100% (target) | Exploration |
Mandalay/Alkane offers the only profitable production with debt-free status and FCF generation, though Chinese processing dependence limits strategic value. UAMY trades at a significant premium to fundamentals but reflects its irreplaceable position as the only integrated Western producer.
Scoring criteria and weights:
| Rank | Company | Score | Bull Case ($35K/t) | Primary Risk |
|---|---|---|---|---|
| 1 | Larvotto Resources (LRV) | 87/100 | A$1.3-1.5B (~2x upside) | Execution; rejected takeover creates uncertainty |
| 2 | United States Antimony (UAMY) | 83/100 | $1.5-2.0B (50-100% upside) | Feedstock supply; negative EBITDA |
| 3 | Perpetua Resources (PPTA) | 78/100 | $4-5B (25-50% upside) | Litigation; 2028 timeline |
| 4 | Mandalay/Alkane (ALK) | 74/100 | A$1.5B (50% upside) | Chinese processing dependence |
| 5 | Nova Minerals (NVA) | 68/100 | A$800M+ (50-200% upside) | Execution; pre-production |
| 6 | Americas Gold & Silver (USAS) | 65/100 | Byproduct optionality | Antimony is minor component |
| 7 | Southern Cross Gold (SXG) | 60/100 | A$2B+ (resource-dependent) | No resource; 5+ year timeline |
| 8 | Military Metals (MILI) | 52/100 | CAD $100M+ (speculative) | Early exploration; years from production |
Larvotto Resources (LRV.AX) — HIGHEST CONVICTION Thesis: Near-term production (Q2 2026) of 7% of global antimony supply with exceptional economics (102% IRR, negative AISC). Fully funded, derisked via offtake, and trading below NPV despite rejected $470M takeover bid. Position: Core holding (5-8% of antimony allocation) Catalyst: Production startup Q2 2026; potential higher takeover offer
United States Antimony (UAMY) — HIGH CONVICTION Thesis: Only integrated Western antimony producer with $352M government/industrial contracts securing revenue visibility. Strategic scarcity commands premium despite current losses. Position: Core holding (5-7% of antimony allocation) Catalyst: Thompson Falls expansion completion (Jan 2026); Montana mining ramp-up
Perpetua Resources (PPTA) — MEDIUM-HIGH CONVICTION Thesis: Largest U.S. antimony reserve with $2B+ government backing. Primarily a gold play but strategic antimony importance de-risks permitting. 2028 production provides 2-year optionality. Position: Moderate position (3-5%) Catalyst: EXIM final approval (Spring 2026); litigation resolution
Mandalay/Alkane (ALK.ASX) — MEDIUM CONVICTION Thesis: Only profitable antimony producer trading at 2x EV/EBITDA. Cheapest valuation in sector with $88M cash and debt-free balance sheet. Position: Moderate position (3-5%) Risk: Chinese smelter dependence undermines strategic positioning
Nova Minerals (NVA.AX) — SPECULATIVE Thesis: DOD-backed Alaska project targeting 2026/27 antimony production. Strategic U.S. domestic supply chain play. Position: Small position (1-3%) Catalyst: Maiden antimony resource; DOD contract announcements
Military Metals (MILI.V) — HIGHLY SPECULATIVE Thesis: Pure-play antimony explorer with EU critical minerals recognition. Maximum leverage to antimony prices upon resource confirmation. Position: Lottery ticket (0.5-1%) Catalyst: Trojarová MRE (early 2026)
Near-term (Q1-Q2 2026):
Medium-term (H2 2026-2027):
Price scenario sensitivity: At $35,000/tonne (40% below current levels), all producing companies remain profitable, though exploration valuations would compress. At $50,000/tonne sustained, Larvotto's NPV exceeds A$1B, UAMY could generate $50M+ EBITDA, and development-stage valuations would re-rate significantly higher.
The antimony investment thesis remains structurally sound: China controls 70%+ of processing, Western capacity takes years to build, and defense demand is price-inelastic. The companies ranked above represent the complete universe of publicly-traded options to capitalize on this critical mineral shortage.